85 related articles for article (PubMed ID: 24828671)
21. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
[TBL] [Abstract][Full Text] [Related]
22. ROS1 rearranged non-small cell lung cancer brain metastases respond to low dose radiotherapy.
Lukas RV; Hasan Y; Nicholas MK; Salgia R
J Clin Neurosci; 2015 Dec; 22(12):1978-9. PubMed ID: 26159887
[TBL] [Abstract][Full Text] [Related]
23. Clinicopathologic analysis of ROS1-rearranged non-small-cell lung cancer and proposal of a diagnostic algorithm.
Go H; Kim DW; Kim D; Keam B; Kim TM; Lee SH; Heo DS; Bang YJ; Chung DH
J Thorac Oncol; 2013 Nov; 8(11):1445-50. PubMed ID: 24128715
[TBL] [Abstract][Full Text] [Related]
24. ROS1 fusions in cancer: a review.
Uguen A; De Braekeleer M
Future Oncol; 2016 Aug; 12(16):1911-28. PubMed ID: 27256160
[TBL] [Abstract][Full Text] [Related]
25. ROS1 gene rearrangement is identified in NSCLC.
Cancer Discov; 2012 Feb; 2(2):OF9. PubMed ID: 22585869
[TBL] [Abstract][Full Text] [Related]
26. ROS1 rearrangements in lung cancer: a new genomic subset of lung adenocarcinoma.
Jänne PA; Meyerson M
J Clin Oncol; 2012 Mar; 30(8):878-9. PubMed ID: 22215755
[No Abstract] [Full Text] [Related]
27. ROS1-Rearranged Non-Small-Cell Lung Cancer, Factor V Leiden, and Recurrent Venous Thromboses.
Lee A; Howell VM; Itchins M; Wheeler HR; Pavlakis N
Clin Lung Cancer; 2018 Sep; 19(5):457-459. PubMed ID: 29945753
[No Abstract] [Full Text] [Related]
28. Comparison of methods in the detection of ALK and ROS1 rearrangements in lung cancer.
Rogers TM; Russell PA; Wright G; Wainer Z; Pang JM; Henricksen LA; Singh S; Stanislaw S; Grille J; Roberts E; Solomon B; Fox SB
J Thorac Oncol; 2015 Apr; 10(4):611-8. PubMed ID: 25789833
[TBL] [Abstract][Full Text] [Related]
29. ROS1 translocations and amplifications in lung cancer brain metastases.
Preusser M; Streubel B; Birner P
J Neurooncol; 2014 Jun; 118(2):425-426. PubMed ID: 24760415
[No Abstract] [Full Text] [Related]
30. Circular RNA F-circSR derived from SLC34A2-ROS1 fusion gene promotes cell migration in non-small cell lung cancer.
Wu K; Liao X; Gong Y; He J; Zhou JK; Tan S; Pu W; Huang C; Wei YQ; Peng Y
Mol Cancer; 2019 May; 18(1):98. PubMed ID: 31118036
[TBL] [Abstract][Full Text] [Related]
31. The oncogenic lung cancer fusion kinase CD74-ROS activates a novel invasiveness pathway through E-Syt1 phosphorylation.
Jun HJ; Johnson H; Bronson RT; de Feraudy S; White F; Charest A
Cancer Res; 2012 Aug; 72(15):3764-74. PubMed ID: 22659450
[TBL] [Abstract][Full Text] [Related]
32. Novel deletion of
Dandan S; Yuqin C; Wei L; Ziheng P; Dapeng Z; Jianzhu Y; Xin X; Yonghong L; Fengjun T
J Genet; 2018 Sep; 97(4):939-944. PubMed ID: 30262706
[TBL] [Abstract][Full Text] [Related]
33. Identification of tumors with NRG1 rearrangement, including a novel putative pathogenic UNC5D-NRG1 gene fusion in prostate cancer by data-drilling a de-identified tumor database.
Ptáková N; Martínek P; Holubec L; Janovský V; Vančurová J; Grossmann P; Navarro PA; Rodriguez Moreno JF; Alaghehbandan R; Hes O; Májek O; Pešek M; Michal M; Ondič O
Genes Chromosomes Cancer; 2021 Jul; 60(7):474-481. PubMed ID: 33583086
[TBL] [Abstract][Full Text] [Related]
34. CD74-NRG1 fusions in lung adenocarcinoma.
Fernandez-Cuesta L; Plenker D; Osada H; Sun R; Menon R; Leenders F; Ortiz-Cuaran S; Peifer M; Bos M; Daßler J; Malchers F; Schöttle J; Vogel W; Dahmen I; Koker M; Ullrich RT; Wright GM; Russell PA; Wainer Z; Solomon B; Brambilla E; Nagy-Mignotte H; Moro-Sibilot D; Brambilla CG; Lantuejoul S; Altmüller J; Becker C; Nürnberg P; Heuckmann JM; Stoelben E; Petersen I; Clement JH; Sänger J; Muscarella LA; la Torre A; Fazio VM; Lahortiga I; Perera T; Ogata S; Parade M; Brehmer D; Vingron M; Heukamp LC; Buettner R; Zander T; Wolf J; Perner S; Ansén S; Haas SA; Yatabe Y; Thomas RK
Cancer Discov; 2014 Apr; 4(4):415-22. PubMed ID: 24469108
[TBL] [Abstract][Full Text] [Related]
35. ROS1 receptor tyrosine kinase, a druggable target, is frequently overexpressed in non-small cell lung carcinomas via genetic and epigenetic mechanisms.
Lee HJ; Seol HS; Kim JY; Chun SM; Suh YA; Park YS; Kim SW; Choi CM; Park SI; Kim DK; Kim YH; Jang SJ
Ann Surg Oncol; 2013 Jan; 20(1):200-8. PubMed ID: 22915320
[TBL] [Abstract][Full Text] [Related]
36. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion.
Rimkunas VM; Crosby KE; Li D; Hu Y; Kelly ME; Gu TL; Mack JS; Silver MR; Zhou X; Haack H
Clin Cancer Res; 2012 Aug; 18(16):4449-57. PubMed ID: 22661537
[TBL] [Abstract][Full Text] [Related]
37. ROS1-targeted therapy in non-small cell lung cancer.
Sequist LV
Clin Adv Hematol Oncol; 2012 Dec; 10(12):827-8. PubMed ID: 23271356
[No Abstract] [Full Text] [Related]
38. Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing.
Jurmeister P; Lenze D; Berg E; Mende S; Schäper F; Kellner U; Herbst H; Sers C; Budczies J; Dietel M; Hummel M; von Laffert M
Lung Cancer; 2015 Feb; 87(2):122-9. PubMed ID: 25534130
[TBL] [Abstract][Full Text] [Related]
39. A novel fusion of TPR and ALK in lung adenocarcinoma.
Choi YL; Lira ME; Hong M; Kim RN; Choi SJ; Song JY; Pandy K; Mann DL; Stahl JA; Peckham HE; Zheng Z; Han J; Mao M; Kim J
J Thorac Oncol; 2014 Apr; 9(4):563-6. PubMed ID: 24736082
[TBL] [Abstract][Full Text] [Related]
40. Cytological findings of ROS1-rearranged lung adenocarcinoma.
Kuroda N; Tamiya H; Nakatani K; Ide H; Wada Y; Yasuoka K; Ohara M; Mizuno K; Yorita K; Takeuchi K
Diagn Cytopathol; 2018 Apr; 46(4):336-339. PubMed ID: 29076659
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
